Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting
| Autor: | Claudia Hawkins, Donna Spiegelman, Ferdinand Mugusi, Eric Aris, James Okuma, Wafaie W. Fawzi, Ellen Hertzmark, Guerino Chalamilla, Deo Mtasiwa, Tarcila Ewald |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Multivariate analysis Adolescent Immunology HIV Infections Tanzania Young Adult Acquired immunodeficiency syndrome (AIDS) Risk Factors Internal medicine medicine Humans Immunology and Allergy Prospective Studies Young adult Prospective cohort study Sex Characteristics Proportional hazards model business.industry Hazard ratio Urban Health Middle Aged medicine.disease CD4 Lymphocyte Count Surgery Treatment Outcome Infectious Diseases Anti-Retroviral Agents Cohort Female business Sex characteristics |
| Zdroj: | AIDS. 25:1189-1197 |
| ISSN: | 0269-9370 |
| DOI: | 10.1097/qad.0b013e3283471deb |
| Popis: | Objective: To determine the relationship between sex and antiretroviral therapy (ART) outcomes in an urban Tanzanian setting. Design: Longitudinal analysis of a cohort of HIV-infected adult men and women on ART enrolled at the Management and Development for Health (MDH)-President's Emergency Plan For AIDS Relief (PEPFAR) HIV care and treatment program in Dar es Salaam, Tanzania. Methods: Clinical and immunologic responses to ART were compared between HIV-infected men and women enrolled from November 2004 to June 2008. Cox regression analyses were used to study sex differences with regard to mortality, immunologic failure (WHO, 2006) and loss to follow-up, after adjusting for other risk factors for the outcomes. Results: Four thousand, three hundred and eighty-three (34%) men and 8459 (66%) women were analyzed. Men were significantly more immunocompromised than women at enrollment in terms of stage IV disease (27 vs. 23%, P < 0.001) and mean CD4 + cell count (123 vs. 136 cells/μl, P< 0.001). In multivariate analyses, men had a significantly higher risk of overall mortality [hazard ratio 1.19, 95% confidence interval (CI) 1.05-1.30, P < 0.001], immunologic nonresponse defined as CD4 cell count less than 100 cells/μl after at least 6 months of initiating ART (hazard ratio 1.74, 95% CI 1.44-2.11, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|